Phosphodiesterase-5 (PDE5) is an enzyme which degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. The common known drug Viagra is similar in molecular structure to cGMP and acts as a competitive binding agent of PDE5. Thus in the presence of Viagra unbound cGMP levels increase which results in smooth muscle relaxation or vasodilation leading to an increased inflow of blood. Vanderbilt researchers have developed a method for assaying compounds which bind PDEs. Not only will this method be useful in identify other PDE inhibitors but due to the high affinity of this system this method could be used to identify and isolate PDEs from various crude tissue fractions.
Vanderbilt scientists have modified the currently used tuberculosis vaccine, bacillus Calmette-Guérin (BCG), so that it accesses the immune system in a manner that produces favorable cellular immune responses. The Vanderbilt vaccine, called pro-apoptotic BCG (paBCG)
Isolated and purified lipoxygenase proteins and nucleic acids are described. Particularly, a novel human 15(S) lipoxygenase (15-Lox-2) protein and cDNA and a cDNA for mouse 8S-lipoxygenase are described. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also described, along with methods of producing each. Isolated and purified antibodies to 15-Lox-2 and 8-Lox, and methods of producing the same, are also described.
This invention relates to fatty acid 13-hydroperoxide lyase protein from guava (Psidium guajava) and the gene encoding the protein. Expression systems for recombinant guava 13-hydroperoxide lyase and methods of using recombinant guava 13-hydroperoxide lyase for the production of green notes are provided.
An isolated nucleic acid encoding the Helicobacter pylori recombinase comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. Also provided is an isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 1 under stringent conditions and has at least 70% complementarity with the segment of the nucleic acid of SEQ ID NO:1 to which it hybridizes. Also provided is a mutant strain of H. pylori that does not express a functional recombinase (recA.sup.- mutant). An immunogenic amount of the recA.sup.- mutant H. pylori in a pharmaceutically acceptable carrier is provided. A method of immunizing a subject against infection by H. pylori comprises administering to the subject an immunogenic amount of mutant H. pylori in a carrier for the mutant.
The technology provides a method for diagnosis of MS by detection of Chlamydia and treatment of MS by total eradication of Chlamydia. This technology provides for eradication of Chlamydia by a novel treatment of combining various anti-chlamydial agents directed at different phases of the chlamydial life cycle.
Purified BMP-15-related proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-15-related proteins are also disclosed. The proteins may be used in the treatment of bone and cartilage and/or other connective tissue defects and in wound healing and related tissue repair.
Scientists at Vanderbilt have developed a unique polypeptide using cell-penetrating SOCS polypeptides or SOCS sequences designed to inhibits cytokine signaling and thus prevent or treat inflammation or an inflammatory related disease such as diabetes. This strategy has been validated in NOD mice models for either induced or naturally occurring diabetes and have been efficacious.
A composition comprising a nuclear localization sequence and a peptide nucleic acid oligomer (NLS-PNA) is described. Uses of the composition include, but are not limited to: regulation of gene expression, gene therapy, and the production of pharmaceutical nucleic acids and proteins. In addition, the NLS-PNA is useful for scientific and therapeutic transfection and expression of nucleic acids in cells types that previously were resistant to transfection and therapy including quiescent cells, differentiated cells, embryonic stem cells, and eukaryotic cells with intact nuclear membranes. The NLS-PNA can be combined with a membrane transport sequence (MTS) forming a novel compound referred to as an MTS-NLS-PNA wherein the MTS provides transport through the cytoplasmic membrane of a cell. A nuclear targeted peptide nucleic acid oligomer is useful for the treatment of genetic based diseases and diseases that can be treated genetically including heart disease, cancer, cerebrovascular diseases, chronic pulmonary diseases, human immunodeficiency virus, and other diseases, conditions and disorders.
Method and apparatus to measure jitter (period-to-period fluctuations in fundamental frequency) among the voices of suicidal, major depressed, and non-suicidal patients to predict near-term suicidal risk.
The invention describes a membrane-translocating peptide sequence (MTS) which facilitates entry of polypeptides and proteins into cells. Also described is an isolated nucleotide sequence encoding the membrane-translocating peptide and a method of using this sequence to genetically engineer proteins with cell membrane permeability. The MTS, and the method of genetically engineering proteins with cell membrane permeability, are useful for polypeptide and protein delivery for human and veterinary applications such as vaccine delivery and cancer therapy.
A method of chemical ligation of peptides that requires no side chain protecting groups and no activation of the C-.alpha. carboxyl group is presented. The method consists of three steps. In the first step, initiation, a masked glycoaldehyde ester is enzymatically or chemically coupled to the C-terminal carboxylic acid of an sidechain unprotected first peptide. In the second step, ring formation, the masked aldehyde ester of the first peptide is unmasked, and then reacted with the N-.alpha. amino acid of a second sidechain unprotected peptide to form a ring structure. In the third step, rearrangement, the O-acyl ester linkage transfers at higher pH to an N-acyl linkage on the ring to form a peptide bond.